Goldman Sachs has agreed to invest US$37 million in Venus Medtech, a Hangzhou-based healthcare company focused on research and development of heart valves disease related medical products and services, according to a company announcement.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!Register Now
Already have an account or paid subscription?